U.S. equities are poised for a flat open on Thursday as traders digest a fresh record high for small-cap stocks and brace for the latest producer price data. The Russell 2000 finished Wednesday at 3,045.48, up 0.6% and surpassing its prior peak of 3,036.98, marking its 27th record close of 2026. The index has now climbed 22.7% year-to-date, outpacing the S&P 500 by 9.5 percentage points.
The surge in small caps has been fueled by expectations that the Federal Reserve may soon ease monetary policy. Wednesday's consumer price index showed overall prices rose just 0.1% in July, bringing the annual rate to 3.4%, while core inflation increased 0.2% month-over-month and 2.5% year-over-year. That softer-than-expected reading reduced the odds of a September rate hike to 40%, down from roughly 54% a week ago.
Thursday's producer price index, due at 8:30 a.m. EDT, is the next key catalyst. Economists forecast a 0.3% monthly increase in core producer prices, following a 0.2% gain in June. A hotter-than-expected print could reignite inflation worries and push Treasury yields higher, potentially derailing the small-cap rally. Conversely, a cool reading would reinforce the case for rate cuts and extend the rotation into smaller companies.
Major futures were little changed ahead of the release, with S&P 500 e-minis up 0.12% and Nasdaq 100 e-minis gaining 0.2%. The yield on the 10-year Treasury note dipped to 4.678%, reflecting modest optimism. Lower borrowing costs are particularly beneficial for small caps, which rely more heavily on floating-rate debt and have higher beta to economic growth.
"Markets are holding up fairly well due to solid economic growth that is picking up pace," said Olga Bitel, chief investment strategist at William Blair Investment Management. She expects sector leadership to shift even if the overall market remains stable. The iShares Russell 2000 ETF (IWM), which tracks the index, holds 1,967 stocks, with health care and financials together accounting for 39.86% of the portfolio as of July 29.
That sector mix heightens sensitivity to interest rates. Financials stand to benefit from stronger growth but face margin pressure if funding costs remain elevated. Health care includes many early-stage biotech firms whose valuations hinge on future cash flows, making them vulnerable to higher discount rates. With a three-year beta of 1.27, the Russell 2000 is more volatile than the broader market.
Wall Street strategists are divided on the small-cap outlook. Bank of America has a positive stance, arguing that stronger earnings momentum, increased capital spending, and lower relative valuations will drive outperformance. Goldman Sachs is more cautious, projecting only modest gains in the second half due to the index's smaller AI exposure and higher proportion of floating-rate liabilities. Wells Fargo recommends reducing exposure, citing lagging returns and debt ratios.
The producer price report will provide a crucial test. If yields stay low and Russell futures maintain Wednesday's breakout, small caps may extend their lead. However, an unexpected jump in wholesale prices could trigger a reversal, prompting investors to reassess the sustainability of the record run. The market's reaction will likely set the tone for the remainder of the week.
